ABSTRACT
Objective: The purpose of this paper is to summarize the blood purification technology applied in patients with severe fever with thrombocytopenia syndrome (SFTS) in the clinical treatment effect. Methods: The medical records of 96 patients with severe SFTS admitted to Weihai Municipal Hospital affiliated to Shandong University from May 2014 to November 2019 were retrospectively analyzed, and they were divided into survival group and death group. The differences in basic data test indexes and treatment method selection during intensive care unit (ICU) admission between the two groups were significantly analyzed, and the indexes with statistically significant differences were included in the multivariate logistic regression analysis related to prognosis. Results: There were no statistically significant differences in age, sex composition, white blood cell count, platelet count, creatine kinase (CK), activated partial thromboplastin time (APTT), serum creatinine and hemofiltration renal replacement therapy between the survival group and the death group. There were statistically significant differences between the two groups in viral load bilirubin and the treatment methods of plasma exchange (PE) or hemoperfusion (HP). Plasma exchange group (78 cases), hemofiltration group (12 cases), hemoperfusion group (6 cases), plasma exchange and hemoperfusion and other blood purification treatment of the prognosis were statistically different. Conclusions: Compared with the three blood purification methods, plasmapheresis has a significant effect on virus removal, improvement of coagulation function and survival rate in patients with severe SFTS. Hemofiltration plays a role in removing inflammatory mediators, replacing renal function, maintaining electrolytes and acid-base balance, but not in removing viruses.
Acknowledgements
Not applicable
Disclosure statement
No potential conflict of interest was reported by the authors.
Data Availability Statement
All data used to support the findings of this study are included within the article.
Additional information
Funding
Notes on contributors
Hongxia Gao
Hongxia Gao, graduated from Jinzhou Medical University, has been engaged in intensive care medicine for more than ten years, and has rich clinical experience in severe infection.
Baoyin Wang
Baoyin Wang, graduated from Jilin University, has been engaged in intensive care medicine for more than 20 years, and has rich clinical experience in severe infection.
Hui Yao
Hui Yao, a doctor with a master's degree in intensive care medicine, has rich clinical experience in severe infection.
Wenjie Zhang
Wenjie Zhang, has been engaged in intensive care medicine for more than 20 years and has rich clinical experience in severe infection.
HaiFeng Teng
Haifeng Teng, graduated from Shandong University, has been engaged in intensive care medicine for more than ten years, and has rich clinical experience in severe infection.